Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

The mTORC1 inhibitor everolimus prevents and treats E?-Myc lymphoma by restoring oncogene-induced senescence

Thumbnail Image

Date

2013

Authors

Wall, Meaghan
Poortinga, Gretchen
Stanley, Kym L.
Lindemann, Ralph K.
Bots, Michael
Chan, Christopher J
Bywater, Megan J.
Kinross, Kathryn M.
Astle, Megan V.
Waldeck, Kelly

Journal Title

Journal ISSN

Volume Title

Publisher

American Association for Cancer Research

Abstract

MYC deregulation is common in human cancer. IG-MYC translocations that are modeled in EμMyc mice occur in almost all cases of Burkitt lymphoma as well as in other B-cell lymphoproliferative disorders. Deregulated expression of MYC results in increased mT

Description

Keywords

Keywords: etoposide; everolimus; Myc protein; placebo; protein p53; animal cell; animal experiment; animal model; animal tissue; article; B lymphocyte; bone marrow; cancer specific survival; cell cycle; cell differentiation; cell transformation; controlled study; f

Citation

URI

http://hdl.handle.net/1885/67129

Collections

ANU Research Publications

Source

Cancer Discovery

Type

Journal article

Book Title

Entity type

Access Statement

License Rights

DOI

10.1158/2159-8290.CD-12-0404

Restricted until

2037-12-31

Downloads

File
Description
01_Wall_The_mTORC1_inhibitor_2013.pdf (8.54 MB)

DSpace software copyright © 2002-2026 LYRASIS